Balyasny Asset Management L.P. Takes Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Balyasny Asset Management L.P. purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,700 shares of the medical research company's stock, valued at approximately $1,052,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of CRL. D1 Capital Partners L.P. acquired a new stake in Charles River Laboratories International in the fourth quarter valued at $172,752,000. Norges Bank purchased a new position in shares of Charles River Laboratories International during the fourth quarter worth about $98,886,000. Wellington Management Group LLP grew its holdings in shares of Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after purchasing an additional 335,658 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Charles River Laboratories International during the fourth quarter worth about $42,776,000. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Charles River Laboratories International during the fourth quarter worth about $36,968,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Charles River Laboratories International

In related news, COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Joseph W. Laplume sold 500 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the sale, the executive vice president now owns 19,513 shares of the company's stock, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,040 shares of company stock valued at $807,407. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Stock Performance

CRL traded up $0.39 during trading on Monday, reaching $141.36. The company's stock had a trading volume of 752,502 shares, compared to its average volume of 981,981. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The company's fifty day moving average price is $134.84 and its 200-day moving average price is $164.49. The company has a market capitalization of $6.94 billion, a price-to-earnings ratio of 942.40, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same quarter in the previous year, the company earned $2.27 EPS. The firm's revenue for the quarter was down 2.7% compared to the same quarter last year. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on CRL shares. William Blair lowered Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Evercore ISI raised Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price objective on the stock in a report on Thursday, May 8th. Mizuho dropped their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. JPMorgan Chase & Co. dropped their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Finally, Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $172.31.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).